<DOC>
	<DOC>NCT01180426</DOC>
	<brief_summary>The purpose of this study is to evaluate the long-term efficacy and safety profile of tosedostat in elderly patients suffering from refractory or relapsed Acute Myeloid Leukemia.</brief_summary>
	<brief_title>Extension Study With Tosedostat in Relapsed/Refractory Acute Myeloid Leukemia</brief_title>
	<detailed_description>Extension protocol to the OPAL Study (CHR-2797-038). Study mimics normal clinical practice; few procedures and visits are therefore mandated by the protocol. Timing of bone marrow assessment is also left at the investigator's discretion.</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Myeloid</mesh_term>
	<mesh_term>Leukemia, Myeloid, Acute</mesh_term>
	<criteria>Signed, informed consent Completion of Visit 11 in the OPAL Study (Month 6 Visit) Investigator's opinion that the subject would benefit from continued therapy with tosedostat. Any coexisting medical condition that in the Investigator's opinion will substantially increase the risk associated with the subject's participation in the study Psychiatric disorders or altered mental status precluding understanding of the informed consent process and/or completion of the necessary studies Administration of any (other) investigational agent within 14 days of entry into TOPAZ.</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Relapse Refractory Acute Myeloid Leukemia</keyword>
</DOC>